Screening and Prevention of Type 1 Diabetes: Where Are We?

被引:1
|
作者
Simmons, Kimber M. [1 ]
Sims, Emily K. [2 ,3 ]
机构
[1] Univ Colorado, Div Pediat, Barbara Davis Ctr Diabet, Sch Med, Aurora, CO 80045 USA
[2] Herman B Wells Ctr Pediat Res, Div Pediat Endocrinol & Diabetol, 635 Barnhill Dr,MS 2031, Indianapolis, IN 46202 USA
[3] Indiana Univ Sch Med, Ctr Diabet & Metab Dis, 635 Barnhill Dr,MS 2031, Indianapolis, IN 46202 USA
来源
关键词
type; 1; diabetes; screening; prevention; pediatric; BETA-CELL FUNCTION; MULTIPLE ISLET AUTOANTIBODIES; B-LYMPHOCYTE DEPLETION; C-PEPTIDE; DOUBLE-BLIND; HIGH-RISK; DIAZOXIDE TREATMENT; NATURAL-HISTORY; FAMILY-HISTORY; ORAL INSULIN;
D O I
10.1210/clinem/dgad328
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
A diagnosis of type 1 diabetes (T1D) and the subsequent requirement for exogenous insulin treatment is associated with considerable acute and chronic morbidity and a substantial effect on patient quality of life. Importantly, a large body of work suggests that early identification of presymptomatic T1D can accurately predict clinical disease, and when paired with education and monitoring, can yield improved health outcomes. Furthermore, a growing cadre of effective disease-modifying therapies provides the potential to alter the natural history of early stages of T1D. In this mini review, we highlight prior work that has led to the current landscape of T1D screening and prevention, as well as challenges and next steps moving into the future of these rapidly evolving areas of patient care.
引用
收藏
页码:3067 / 3079
页数:13
相关论文
共 50 条
  • [1] Prevention of type 1 diabetes: where we are and where we are going
    Frontino, Giulio
    Guercio, Nuzio S.
    Scaramuzza, Andrea
    D'Annunzio, Giuseppe
    Toni, Sonia
    Citriniti, Felice
    Bonfanti, Riccardo
    [J]. MINERVA PEDIATRICS, 2021, 73 (06): : 486 - 503
  • [2] Prevention of type 1 diabetes: Where do we start?
    P. Pozzilli
    L. Adorini
    [J]. Journal of Endocrinological Investigation, 2003, 26 : 292 - 293
  • [3] Prevention of type I diabetes: Where do we start?
    Pozzilli, P
    Adorini, L
    [J]. JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2003, 26 (04) : 292 - 293
  • [4] Type 1 diabetes: where are we in 2017?
    Copenhaver, Melanie
    Hoffman, Robert P.
    [J]. TRANSLATIONAL PEDIATRICS, 2017, 6 (04) : 359 - 364
  • [5] Children with type 1 diabetes: where are we at?
    Couper, JJ
    [J]. MEDICAL JOURNAL OF AUSTRALIA, 2002, 177 (05) : 228 - 229
  • [6] Screening for type 2 diabetes-where are we now?
    Rutten, Guy
    [J]. LANCET, 2010, 375 (9723): : 1324 - 1326
  • [7] Immunotherapy of Type 1 Diabetes: Where Are We and Where Should We Be Going?
    Luo, Xunrong
    Herold, Kevan C.
    Miller, Stephen D.
    [J]. IMMUNITY, 2010, 32 (04) : 488 - 499
  • [8] Statin Use as a Primary Prevention in Patients with Type 1 Diabetes: Where Do We Stand?
    Ali, Dalal S. A.
    Griffin, Tomas P.
    Crowley, Rachel
    Canavan, Ronan
    [J]. DIABETES, 2021, 70
  • [9] Islet transplantation for Type 1 diabetes: where are we now?
    Ahearn, Aaron J.
    Parekh, Justin R.
    Posselt, Andrew M.
    [J]. EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2015, 11 (01) : 59 - 68
  • [10] Hope vs hype: where are we in type 1 diabetes?
    Jay S. Skyler
    [J]. Diabetologia, 2018, 61 : 509 - 516